In July 2024, announced results of A$55.9 million (US$36.9 million) retail entitlement offer, representing the final stage of the approximately A$227.3 million (US$150.0 million) capital raising ...

Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and ...

Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of ...